Shares of Evelo Biosciences, Inc. (NASDAQ:EVLO) have been given an average rating of “Buy” by the seven research firms that are currently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $21.92.
Several research analysts have commented on the company. BMO Capital Markets reaffirmed a “buy” rating and set a $23.00 target price on shares of Evelo Biosciences in a report on Sunday, October 31st. Jefferies Financial Group cut their target price on Evelo Biosciences from $18.00 to $14.00 and set a “buy” rating on the stock in a report on Tuesday, September 28th. JMP Securities cut their target price on Evelo Biosciences from $44.00 to $41.50 and set a “market outperform” rating on the stock in a report on Tuesday, November 2nd. Chardan Capital raised Evelo Biosciences from a “neutral” rating to a “buy” rating and set a $12.00 target price on the stock in a report on Monday, November 1st. They noted that the move was a valuation call. Finally, Zacks Investment Research raised Evelo Biosciences from a “sell” rating to a “hold” rating in a report on Monday, November 15th.
Several large investors have recently made changes to their positions in the company. FMR LLC lifted its stake in shares of Evelo Biosciences by 0.6% in the 1st quarter. FMR LLC now owns 3,325,107 shares of the company’s stock valued at $26,601,000 after purchasing an additional 19,100 shares during the period. Credit Suisse AG increased its position in Evelo Biosciences by 7.0% in the 3rd quarter. Credit Suisse AG now owns 3,310,911 shares of the company’s stock valued at $23,309,000 after buying an additional 215,192 shares in the last quarter. BlackRock Inc. increased its position in Evelo Biosciences by 13.1% in the 2nd quarter. BlackRock Inc. now owns 1,843,502 shares of the company’s…
